Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials.

Annalise Rahman-Filipiak,Corey Bolton,Joshua D Grill,Ayda Rostamzadeh,Nathaniel Chin,Judith Heidebrink,Sarah Getz,Nicole R Fowler,Allyson Rosen,Jennifer Lingler,Ellen Wijsman,Lindsay Clark

Alzheimer's & dementia : the journal of the Alzheimer's Association（2023）

引用 0|浏览4

暂无评分

摘要

Few prodromal Alzheimer's disease (AD) trial papers discuss biomarker disclosure. Disclosure has implications for participants, family members, and trial success. Disclosure must be consistently integrated and reported in prodromal AD trials. Best practice guidelines and training resources for disclosure are needed.

查看译文

关键词

amyloid, biomarker disclosure, mild cognitive impairment, prodromal Alzheimer's disease, randomized controlled trials

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要